NCT02301364 - Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 20, 2014

Primary Completion Date

October 11, 2016

Study Completion Date

October 11, 2016

Conditions

LymphomaPrimary Central Nervous System LymphomaRecurrent/Refractory Secondary Central Nervous System Lymphoma

Interventions

DRUG

Buparlisib (BKM120)

Buparlisib 100 mg once daily.

Trial Locations (4)

Memorial Sloan Kettering Cancer Center, New York

Memorial Sloan Kettering West Harrison, Harrison

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

Memoral Sloan Kettering Cancer Center, Basking Ridge